AI
LXRX icon

Analytic Investors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Analytic Investors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.05M Sell
58,273
-20,398
-26% -$328K 0.01% 363
2016
Q2 		$1.13M Buy
78,671
+68,589
+680% +$930K 0.01% 361
2016
Q1 		$120K Buy
+10,082
New +$106K ﹤0.01% 587

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Analytic Investors's LXRX Position: Q3 2016 in Review

Analytic Investors reduced its Lexicon Pharmaceuticals (LXRX) stake by 26% in Q3 2016, selling an estimated $328K and leaving 58,273 shares worth $1.05M. The position accounts for 0.01% of the portfolio, ranked #363.

Analytic Investors first reported a position in LXRX in Q1 2016 and has held it in 3 quarters since. The position peaked at $1.13M in Q2 2016. 142 funds tracked by Wall St. Rank hold LXRX as of Q3 2016.

  • Analytic Investors held 58,273 shares of Lexicon Pharmaceuticals worth $1.05M as of Q3 2016.
  • Analytic Investors sold 20,398 Lexicon Pharmaceuticals shares in Q3 2016, an estimated $328K.
  • Lexicon Pharmaceuticals made up 0.01% of Analytic Investors's portfolio in Q3 2016, its #363 holding.
  • Analytic Investors first reported a position in Lexicon Pharmaceuticals in Q1 2016 and has held it in 3 quarters since.
  • Analytic Investors's Lexicon Pharmaceuticals position peaked at $1.13M in Q2 2016.
  • 142 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2016.

Based on Analytic Investors's 13F filing for Q3 2016, filed 14 Nov 2016.